New drug combo tested in kids with aggressive brain tumors
NCT ID NCT05081180
Summary
This study is testing a two-drug combination (avelumab and lenvatinib) in children with aggressive brain tumors that have returned or progressed after prior treatment. The first part aims to find a safe dose, while the second part will see if the combination can slow tumor growth. It involves 17 children with specific types of high-grade central nervous system tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Angers - Hôpital Hôtel Dieu - Service de Cancérologie Pédiatrique
Angers, France
-
CHU Sainte-Justine
Montreal, Canada
-
Hôpital de la Timone
Marseille, France
-
Institut Curie - Centre de Lutte Contre le Cancer (CLCC) de Paris
Paris, France
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, South Korea
-
The Hospital for Sick Children
Toronto, Canada
-
Universitaetsklinikum Hamburg Eppendorf
Hamburg, Germany
-
Universitaetsklinikum Muenster
Münster, Germany
Conditions
Explore the condition pages connected to this study.